Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden

Hepatitis Monthly

Volumn 16, Issue 7, 2016, Pages

  Hajarizadeh, Behzad ^a   Razavi Shearer, Devin ^b   Merat, Shahin ^c,d   Alavian, Seyed Moayed ^e,f   Malekzadeh, Reza ^c,d   Razavi, Homie ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Center for Disease Analysis   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f Middle East Liver Diseases Research Center   (Iran)

Author keywords

Decompensated cirrhosis; Diagnosis; Epidemiology; Hepatitis C; Hepatocellular carcinoma; Mortality; Public health; Treatment

Indexed keywords

PEGINTERFERON;

ADULT; ARTICLE; DISEASE COURSE; DISEASE TRANSMISSION; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HEPATITIS C VIRUS; HUMAN; INCIDENCE; IRAN; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; MORTALITY; PATHOGEN LOAD; PRACTICE GUIDELINE; PREVALENCE; VACCINATION;

EID: 84990303165     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.37234     Document Type: Article

References (35)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCVinfection. Nat Rev Gastroenterol Hepatol. 2013;10(9):553-62. doi: 10.1038/nrgastro.2013.107. [PubMed: 23817321].
2. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31 Suppl 2:61-80. doi: 10.1111/j.1478-3231.2011.02540.x. [PubMed: 21651703].
3. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitisCvirus infection. J Hepatol. 2014;61(Suppl 1):S45-57. doi: 10.1016/j.jhep.2014.07.027. [PubMed: 25086286].
4. Alavian SM. Ministry of Health in Iran is serious about controlling hepatitis B. Hepat Mon. 2007;7(1):3-5.
5. Alavian SM, Gooya M, Hajarizadeh B, Esteghamati A, Moeinzadeh A, Haghazali M, et al. Mass vaccination campaign against hepatitis B in adolescents in Iran: estimating coverage using administrative data. Hepat Mon. 2009;9(3):189-95.
6. Alavian SM, Zamiri N, Gooya MM, Tehrani A, Heydari ST, Lankarani KB. Hepatitis B vaccination of adolescents: a report on the national program in Iran. J Public Health Policy. 2010;31(4):478-93. doi: 10.1057/jphp.2010.35. [PubMed: 21119653].
7. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57(2):230-6. doi: 10.1093/cid/cit234. [PubMed: 23616492].
8. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303-13. [PubMed: 11984517].
9. Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, et al. Pegaferon in hepatitis C: Results of a Multicenter Study. Middle East J Dig Dis. 2011;3(2):110-4. [PubMed: 25197541].
10. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of "perfectovir". Clin Infect Dis. 2015;60(12):1829-36. doi: 10.1093/cid/civ197. [PubMed: 25761867].
11. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12(5):284-92. doi: 10.1038/nrgastro.2015.53. [PubMed: 25895822].
12. Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H. Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study. Hepat Mon. 2012;12(9):e6618. doi: 10.5812/hepatmon.6618. [PubMed: 23087764].
13. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first populationbased study from Iran. Int J Infect Dis. 2010;14 Suppl 3:113-6. doi: 10.1016/j.ijid.2009.11.032. [PubMed: 20362479].
14. Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, Sepanlou SG, et al. The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One. 2011;6(8):e23830. doi: 10.1371/journal.pone.0023830. [PubMed: 21887326].
15. Babak S, Fatemehshamsedin S, Hossein K, Mansour R, Tannaz A, Siavash V, et al. Seroepidemiology of hepatitis C in Kermanshah(West of Iran, 2006). Hepatitis Monthly. 2008;2008(2, Spring):141-6.
16. Shakeri MT, Nomani H, Ghayour Mobarhan M, Sima HR, Gerayli S, Shahbazi S, et al. The prevalence of hepatitis C virus in mashhad, iran: a population-based study. Hepat Mon. 2013;13(3):e7723. doi: 10.5812/hepatmon.7723. [PubMed: 23745128].
17. Zamani F, Sohrabi M, Poustchi H, Keyvani H, Saeedian FS, Ajdarkosh H, et al. Prevalence and risk factors of hepatitis C virus infection in amol city, north of iran: a population-based study (2008-2011). Hepat Mon. 2013;13(12):e13313. doi: 10.5812/hepatmon.13313. [PubMed: 24358039].
18. Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movaghar A, Amin-Esmaeili M, Noroozi A. High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012). Int J Infect Dis. 2015;40:116-30. doi: 10.1016/j.ijid.2015.09.022. [PubMed: 26460088].
19. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection amonginjecting drug users in Tehran. Int J Drug Policy. 2007;18(5):359-63. doi: 10.1016/j.drugpo.2007.02.007. [PubMed: 17854723].
20. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, andhumanimmunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9(4):319-23. [PubMed: 17061602].
21. Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010;14(3):253-62. doi: 10.1111/j.1542-4758.2010.00437.x. [PubMed: 20491973].
22. Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, et al. The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm - volume 3. J Viral Hepat. 2015;22 Suppl 4:21-41. doi: 10.1111/jvh.12476. [PubMed: 26513446].
23. United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: The 2015 revision, key findings and advance tables. New York, USA: United Nations. 2015.
24. Keyvani H, Alizadeh AH, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res. 2007;37(2):101-3. doi: 10.1111/j.1872-034X.2007.00015.x. [PubMed: 17300704].
25. HIV surveillance in the WHOE astern Mediterranean region: Regional update 2012. World Health Organization. Regional Office for the Eastern Mediterranean. 2013.
26. University of California Berkeley. The Human Mortality Database. Max Planck Institute for Demographic Research 2015. [cited 28 Aug]. Available from: http://www.mortality.org.
27. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41(6):497-520. doi: 10.1111/apt.13090. [PubMed: 25616122].
28. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008;93(1-2):141-7. doi: 10.1016/j.drugalcdep.2007.09.008. [PubMed: 17997050].
29. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS. 2010;24(12):753-62. doi: 10.1089/apc.2010.0142. [PubMed: 21138381].
30. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev. 2012;31(7):918-24. doi: 10.1111/j.1465-3362.2012.00468.x. [PubMed: 22612899].
31. Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016;111(2):311-9.
32. Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270-7. [PubMed: 20425880].
33. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendationsfromthe Centers for Disease ControlandPrevention. Ann Intern Med. 2012;157(11):817-22. doi: 10.7326/0003-4819-157-9-201211060-00529. [PubMed: 22910836].
34. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to preventHCVtransmissionamongpeople who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57 Suppl 2:S39-45. doi: 10.1093/cid/cit296. [PubMed: 23884064].
35. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015;386(9995):743-800.